#REDIRECT [[TTFields Optune Lua]]
...
33 bytes (4 words) - 22:34, 29 May 2026
<!-- dedup-label: TTFields/Optune Lua canonical: STELLAR final, HDE-only regulatory, TIGER registry, M
|title=TTFields / Optune Lua for Mesothelioma: STELLAR Trial, FDA HDE Approval & 2026 Treat
...
73 KB (9,572 words) - 17:52, 20 May 2026
...tion M1 disease, treatment options including nivolumab plus ipilimumab and TTFields, prognosis, palliative care, and legal rights.
...elioma, M1 mesothelioma, nivolumab ipilimumab mesothelioma, CheckMate 743, TTFields mesothelioma
...
42 KB (5,664 words) - 14:51, 26 May 2026
...), immunotherapy (nivolumab-ipilimumab, pembrolizumab), radiation therapy, TTFields, CAR-T cell therapy, multimodal approaches, and palliative care.
...decortication, extrapleural pneumonectomy, radiation therapy mesothelioma, TTFields mesothelioma, CAR-T mesothelioma, palliative care mesothelioma, mesotheliom
...
55 KB (6,941 words) - 05:05, 25 May 2026
* '''TTFields is the only cost-effective mesothelioma treatment''' — at $89,808 per QALY
...per month based on manufacturer pricing. A cost-effectiveness study found TTFields added an average of $59,663 in lifetime costs compared to standard therapy,
...
39 KB (4,960 words) - 05:05, 25 May 2026
=== Tumor Treating Fields (TTFields) ===
...the 2025 ASCO guideline states there is insufficient evidence to recommend TTFields, citing very low quality evidence.<ref name="asco2025" />
...
48 KB (5,868 words) - 23:25, 14 May 2026
=== Tumor Treating Fields (TTFields) ===
...
28 KB (3,459 words) - 13:51, 23 May 2026
=== What About Tumor Treating Fields (TTFields)? ===
...Aerts JG, Dziadziuszko R, et al. Final results of Phase II STELLAR trial: TTFields with chemotherapy in unresectable malignant pleural mesothelioma. ''Ann Onc
...
51 KB (6,599 words) - 14:18, 25 April 2026
| style="padding:10px;" | TTFields (Optune Lua)
...
14 KB (1,832 words) - 05:05, 25 May 2026
=== TTFields/Optune Lua ===
TTFields (tumor treating fields), delivered via the Optune Lua device (Novocure), re
...
111 KB (14,507 words) - 23:25, 14 May 2026
* '''Tumor Treating Fields (TTFields):''' Multi-hospital review studying TTFields for mesothelioma; emerging data from combination with standard chemotherapy
...vances (2025): CAR-T, CRISPR, viral gene therapy, BAP1-targeted therapies, TTFields, combination immunotherapy + gene therapy. Mesothelioma Attorney, https://m
...
43 KB (5,359 words) - 23:24, 14 May 2026
...tments with rigorous monitoring. Both CheckMate 743 and the STELLAR trial (TTFields) demonstrated meaningful survival improvements over standard care.<ref name
...larly immunotherapy (nivolumab plus ipilimumab) and tumor treating fields (TTFields) — have meaningfully improved survival expectations since 2020. Additionall
...
45 KB (5,643 words) - 23:25, 14 May 2026
...vs. 6%), pembrolizumab/pemetrexed/platinum (September 17, 2024; HR 0.79); TTFields device (HDE only, 2019)<ref name="dandell-meso" /><ref name="keynote-483" /
...l has been registered, and NCCN/ASCO guidelines do not prominently feature TTFields due to the absence of randomized data.<ref name="mesonet-treatment" />
...
62 KB (7,842 words) - 23:25, 14 May 2026
* [[TTFields Optune Lua]]
...
28 KB (3,537 words) - 23:25, 14 May 2026
=== Tumor Treating Fields (TTFields/Optune) ===
'''Definition:''' Tumor Treating Fields (TTFields), delivered through the Optune Lua device, is a novel treatment that uses l
...
218 KB (26,785 words) - 23:07, 14 May 2026
...padding:10px; border-bottom:1px solid #dee2e6;" | '''[[TTFields_Optune_Lua|TTFields (Optune Lua)]]'''
* [[TTFields_Optune_Lua|TTFields / Optune Lua for Mesothelioma]]
...
67 KB (8,772 words) - 23:06, 14 May 2026
...ural Mesothelioma]] — Immunotherapy, MARS 2 trial, CAR-T cell therapy, and TTFields
...
25 KB (2,946 words) - 12:40, 21 May 2026
| style="padding:10px;" | TTFields + chemotherapy improves survival
...
38 KB (4,762 words) - 23:25, 14 May 2026
'''Tumor Treating Fields (TTFields):''' The Optune Lua device, approved via the FDA's Humanitarian Device Exem
* Tumor Treating Fields (TTFields/Optune Lua) combined with chemotherapy achieved median OS of 18.2 months in
...
99 KB (12,540 words) - 13:45, 25 May 2026
..."vt3989" /> The field is also exploring combinations of these approaches — TTFields plus immunotherapy, CAR-T plus checkpoint inhibitors, and chemoimmunotherap
...
61 KB (7,899 words) - 23:55, 29 May 2026
